Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CAO Sells 1,235 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter sold 1,235 shares of the company’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $77.45, for a total value of $95,650.75. Following the sale, the chief accounting officer owned 73,727 shares of the company’s stock, valued at approximately $5,710,156.15. The trade was a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Christine Marie Utter also recently made the following trade(s):

• On Tuesday, January 6th, Christine Marie Utter sold 1,381 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $106,267.95.

PTC Therapeutics Price Performance

NASDAQ PTCT traded down $0.39 during mid-day trading on Thursday, hitting $76.85. The company’s stock had a trading volume of 1,625,361 shares, compared to its average volume of 1,684,365. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50. The stock’s fifty day simple moving average is $76.26 and its two-hundred day simple moving average is $62.43. The firm has a market capitalization of $6.17 billion, a P/E ratio of 8.98 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The business had revenue of $211.01 million for the quarter, compared to analyst estimates of $177.42 million. During the same quarter in the previous year, the business posted ($1.39) EPS. The business’s quarterly revenue was up 7.2% on a year-over-year basis. On average, equities analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PTCT. Smartleaf Asset Management LLC raised its holdings in PTC Therapeutics by 101.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 236 shares in the last quarter. Optiver Holding B.V. boosted its stake in shares of PTC Therapeutics by 96.5% in the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 249 shares in the last quarter. Comerica Bank grew its stake in PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 469 shares during the last quarter. IFP Advisors Inc raised its position in PTC Therapeutics by 68.1% in the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 310 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in PTC Therapeutics by 42.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 295 shares in the last quarter.

Analysts Set New Price Targets

Several research firms recently commented on PTCT. Citigroup boosted their price target on PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Cowen reissued a “hold” rating on shares of PTC Therapeutics in a report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of PTC Therapeutics in a research report on Monday, December 29th. Barclays increased their price target on PTC Therapeutics from $46.00 to $68.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Finally, The Goldman Sachs Group lifted their target price on PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a research note on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, PTC Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $77.27.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent fundamentals still supportive — PTC reported an earnings and revenue beat in its last quarter (Nov.) and maintains strong margins relative to peers, which underpins the stock’s valuation and analyst interest. MarketBeat PTCT profile
• Neutral Sentiment: Small inducement grant: the company approved 300 restricted stock units for a new non‑executive employee on Jan. 2 — immaterial dilution and likely not a major near‑term driver. PR Newswire: Inducement Grants
• Neutral Sentiment: Analyst consensus is a “Hold” with a mixed set of price targets and ratings — this produces limited conviction among buy‑side actors and can temper short‑term moves. Analyst consensus report
• Negative Sentiment: Heavy insider selling disclosed in multiple Form 4s — several executives and directors (including the CEO, CFO, EVP, VPs and others) sold several tens of thousands of shares across Jan. 6–7 at ~\$77 per share, representing millions of dollars of proceeds. Collective insider sales at this scale can put near‑term downward pressure on the stock and signal to some investors that insiders are taking gains. The filings and aggregated alert are here for review. InsiderTrades: Jan. insider sales alert

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.